A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth
A phase 2 trial of Osimertinib, Amivantamab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations is a phase 2 interventional study registered as NCT05801029 by AstraZeneca, with 60 participants enrolled, started 2023-07-18 and due to reach its primary completion in 2027-10-01. Interventions recorded: Osimertinib, Amivantamab. Conditions listed: Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Shares Osimertinib, AstraZeneca, Non-small-cell lung cancer.
- TrialA Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialDurvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Shares Osimertinib, AstraZeneca, Non-small-cell lung cancer.